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Abstract
Background: The purpose of this study was to investigate the effect of Suxiao Jiuxin Pill (SX), a traditional Chinese
medicine, on acute myocardial ischemia induced by coronary occlusion in anesthetized dogs.
Methods: Acute myocardial ischemia model was established by ligating the left anterior descending artery to
reduce flow by 90 %. Adult mongrel dogs were randomly divided into six groups: model, SX high dose, SX middle
dose, SX low dose, Isosorbide dinitrate (ISD) and Sham groups. Adult mongrel dogs were anesthetized and
instrumented for measurements of heart rate (HR), mean arterial pressure (MAP), left ventricular systolic pressure
(LVSP), left ventricular dP/dt, coronary blood flow (CBF), myocardial blood flow (MBF), coronary vascular resistance
(CVR), and epicardial electrocardiogram (EECG). After administration with SX, changes in hemodynamics were
recorded. Serum enzymes and blood gas analysis were also detected.
Results: SX has a dose-dependent effect on the reduction of infarct size. Besides, SX exerted a notable inhibition
on the elevation of serum creatine kinase MB (CK-MB), lactate dehydrogenase (LDH), malondialdehyde (MDA), and
elevation in the superoxide dismutase (SOD) activity. SX also showed a capacity to recover myocardial function by
significantly reducing MAP, CVR, LVSP, left ventricular systolic pressure (LVEDP), systolic blood pressure (SBP),
diastolic blood pressure (SDP), and increasing CBF and myocardial blood flow (MBF). In addition, SX high dose
group markedly reduced total mV of ST segment elevation (Σ-ST), total number of sites with this degree of ST
segment elevation (N-ST) and oxygen extraction ratio (O2 Extr).
Conclusion: SX can improve hemodynamic and myocardial oxygen metabolism, reduce the degree and scope of
myocardial ischemia, and hence exert notable anti-anginal ischaemic effect.
Background
Cardiovascular disease is the leading cause of death
worldwide, affecting not only high-income but also low-
and middle-income countries. Coronary heart disease
(CHD) and ischemic cardiomyopathy are the most im-
portant types of cardiovascular disease [1, 2]. Modern
medicine has improved dramatically as the treatment of
cardiovascular disease. Primary therapies such as antian-
ginal drugs and anticonvulsive drug are the first-line
treatments for cardiovascular disease [3]. At the same
time, some of the traditional Chinese medicine (TCM)
gradually entered into public view because of its remark-
able clinical effect. Traditional Chinese medicine has
about 2000 to 3000 years history with unique theories
for concepts of etiology and systems of diagnose and
cure illness. Chinese medicines have many clinical appli-
cations in treatment of cardiovascular disease, such as
Suxiao jiuxin pill (SX) for Angina Pectoris [4–6].
SX is one of the most efficacious Chinese patent medi-
cines for the treatment of cardiocerebral vascular dis-
eases. It was developed on years of clinical experience by
old Chinese medicine experts – Chenggui Zhang in the
1980s, and manufactured by the Sixth Chinese Drugs
Factory of Tianjin Zhongxin Pharmaceutical Co., Ltd.,
Tianjin, China [7]. It has been used for the treatment of
coronary heart disease, angina pectoris, myocardial
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infarction, and hence added on the national essential
drug list of China with 30 years of clinical application
[8]. SX has been shown to rapid remission of angina
pectoris and improve its symptoms with small doses in
addition there is no obvious discomfort, side effects and
drug resistance [9]. In China, many people who suffer
from angina pectoris take SX to prevent and treat angina
pectoris. Recent studies suggest that SX was shown to
significantly improve myocardial ischaemia and reduce
the incidence of myocardial infarction by improving
microcirculation, reducing the blood viscosity, increasing
coronary arterial blood flow, dilating coronary vessels
and improving myocardial blood supply [10–13]. How-
ever, despite many years of clinical experience in the use
of anti-angina, the corresponding basic research was
relatively scarce.
Ligusticum Chuanxiong (Rhizoma Chuanxiong) and
Borneol (Borneolum Syntheticum) are the two main
components of SX [9]. Ligusticum Chuanxiong is a
popular Chinese medicinal plant with the effect of blood
and Qi circulation, chills and pain relief, and clear
gloomy dampness in traditional Chinese medicine for
thousands of years [14]. Tetramethylpyrazine, a bioactive
ingredient contained in Ligusticum Chuanxiong, is
broadly applied in the treatment of vascular diseases in
China, e. g. myocardial and cerebral infarction [15]. The
average content of tetramethylpyrazine is 0.04084 mg/pill
in SX [16]. Borneol is another major component of SX
and essential oil in many other medicinal plants, as well as
a popular traditional Chinese medicine [17]. Report
showed that borneol shares many bioactivities such as
anti-inflammatory, antithrombotic, and protection against
cerebral ischemic damage [18].
In this study, we utilize the myocardial ischemia model,
ligating left anterior descending (LAD), to investigate the
anti-ischemic effect of SX on hearts. Myocardial infarct
size, blood gas variables, hemodynamic and epicardial
electrocardiogram, and serum levels of creatine kinase
MB (CK-MB), lactate dehydrogenase (LDH), malondialde-
hyde (MDA), and superoxide dismutase (SOD), parame-
ters were measured during the experiment.
Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Regulations on the manage-
ment of laboratory animal [19]. All animal procedures
were performed in accordance with the Animal Ethics
Committee of Tianjin University of Traditional Chinese
Medicine (TCM-2012-011-E05).
Animal
Healthy adult male mongrel dogs (12–18 kg) were used
in this study provided by Beijing Keyu animal breeding
center, and purchased in Tianjin University of Traditional
Chinese Medicine Experimental Animal Center after
ethical and scientific approval. All dogs were kept and
maintained under laboratory conditions of temperature,
humidity, and were allowed free access to food and water.
After one week, 44 healthy dogs were selected by weight
and ECG (the dogs with unqualified weight and ECG were
eliminated), and randomly divided into six groups based
on weight: model (saline, 1 ml/kg), SX high dose (SX,
25.60 mg/ml/kg), SX middle dose (SX, 12.80 mg/ml/kg),
SX low does (SX, 6.40 mg/ml/kg,) and Isosorbide dinitrate
(ISD, 0.80 mg/ml/kg), and Sham (saline, 1 ml/kg) with 7,
7, 9, 7, 6, and 8 animals in each groups respectively.
Animals that died during the experiment were not in-
cluded. SX (40 mg/tablet) were kindly supplied by the
Sixth Chinese Drugs Factory of Tianjin Zhongxin Pharma-
ceutical Co., Ltd.
Surgical preparation
This study was performed using the experimental model
of acute myocardial ischemia (AMI). Dogs were fasted
overnight prior to the surgery, but allowed free access to
water. A previously described model of open chest anes-
thetized dogs was used [20, 21]. Dogs were anesthetized
with 30 mg/kg of i.v. sodium pentobarbital (St. Louis,
MO, USA), and additional doses were given as needed
throughout the experiment. Aseptic surgical technique
was performed, and the dog’s body kept at a constant
temperature by thermostatic operating table. The dogs
were intubated and ventilated by a respirator (DHX-
500, Chengdu of China) with room air (tidal volume,
200 ml/kg per min; respiratory rate, 18 cycles/min). A
polyethylene catheter was inserted into the venous sinus
through the right external jugular vein for venous blood
gas analysis and blood samples. The left femoral artery
was connected with a polyethylene catheter for arterial
blood gas analysis and blood pressure measurement. An 8
to 10 cm thoracotomy was performed in the left fifth
intercostal space and the heart was suspended in a peri-
cardial cradle. The left circumflex coronary artery (LCX)
was isolated 3–5 mm from the origin and an ultrasonic
transit-time perivascular flow probe (2.5 or 3.0 mm, Tran-
sonic Systems Inc., Ithaca, NY, USA) was placed around
LCX to measure coronary blood flow (CBF), as described
recently [22]. A segment of left anterior descending cor-
onary artery (LAD) was isolated between the first and sec-
ond diagonal branch and the blood flow were mesured by
the same method as above. A double 7.0 silk ligature was
passed through the LAD for latter two-stage occlusion.
The double silk ligature was cut, thus becoming two liga-
tures. The first ligature was tightened to reduce flow of
LAD by 50 % for 10 min, and then the second ligature
was tightened with needle to decreases the flow by 90 %
[23]. Sham-operated dogs were subjected to the same
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procedures without LAD ligation. An infusion tube was
inserted into duodenum for drug administration after oc-
clusion. Thirty minutes after LAD ligation, all dogs were
injected through the infusion tube with drugs or saline.
Experimental procedure
Hemodynamic measurements
Coronary angiography catheter (7F) was inserted via the
right femoral artery into the left ventricle by the Seldinger
technique and then connected to the MP150 analogue-to-
digital converter (Biopac Systems, Inc., Goleta, CA). The
heart rate (HR), mean arterial pressure (MAP), left ven-
tricular systolic pressure (LVSP), left ventricular end-
diastolic pressure (LVEDP), the maximum and minimum
first derivative of LVSP (+dP/dtmax and -dP/dtmax) were
measured. Moreover a polyethylene catheter was inserted
to left femoral artery for the measurement of the systolic
blood pressure (SBP), diastolic blood pressure (DBP), and
mean arterial pressure (MAP). The CBF were measured
by an ultrasonic transit-time perivascular flow probe and
recorded by MP150. Myocardial blood flow (MBF, in mil-
liliters per minute per 100 g) was approximately calculated
from the equation: MBF = CBF × 300/Cardiac Weight
[24]. Coronary vascular resistance (CVR) was calculated
by dividing mean arterial pressure (MAP) with the re-
spective MBF [25]. Hemodynamic data were collected at
pre-occlusion, pre-administration, and at all time in
180 min after administration.
Determination of epicardial ECG
Epicardial electrocardiogram (EECG) with 30 unipolar
silver wire electrodes, connected to MP150 were placed
on the anterior surface of the left ventricle. Characteris-
tic electrical parameters such as ECG ST elevations were
recorded from points of a 5 × 6 matrix on the anterior
epicardial surface [26]. All EECG data were analyzed
using the PowerLab software system (Chart version
7.3.7, AD Instruments). The determination of epicardial
ECG was measured at pre-occlusion, pre-administration,
and 30, 60, 90, 120, 180 min after administration. A ST
segment elevation of more than 2 mV was regarded as
the ischemic criteria to calculate the degree of myocar-
dial ischemia (total mV of ST segment elevation, Σ-ST)
and the scope of myocardial ischemia (total number of
sites with this degree of ST segment elevation, N-ST)
[27]. All hemodynamic and cardiodynamic data were
sampled by a laboratory computer at 1000 Hz, and mean
values for 10 cardiac cycles were saved on the laboratory
computer for future analysis.
Serum enzymes activities and blood gas analysis
The blood samples were collected from the venous sinus
and test for CK-MB, LDH, MDA and SOD levels by the
diagnostic kits (Nanjing Jiancheng Bioengineering Institute,
China) with recommended protocol. The venous sinus
blood and arterial blood were sampled anaerobically in
heparinized syringes and immediately analyzed for
analysis of oxygen tensions (PO2) and oxygen satur-
ation (SO2) by a blood gas analyzing machine (Radi-
ometer ABL5, Denmark). Oxygen content of arterial
(CaO2) and venous (CvO2) blood in ml/dl was calculated
as follows [28]: CaO2 = (SaO2 ×Hgb × 1.34) + (0.003 ×
PaO2); CvO2 = (SvO2 ×Hgb × 1.34) + (0.003 × PvO2); oxy-
gen extraction ratio (O2 Extr) = (CaO2 −CvO2)/CaO2;
myocardial oxygen consumption (MVO2) = CBF×(CaO2 −
CvO2), where PaO2 is arterial carbon dioxide tension,
PvO2 is venous sinus oxygen tension, SaO2 is arterial oxy-
gen saturation, Hgb is hemoglobin, SvO2 is venous sinus
oxygen saturation. All blood samples were measured at
pre-occlusion, pre-administration, and 30, 60, 90, 120,
180 min after administration.
Determination of infarct size
After 180 min of occlusion, the heart was removed and
the atrium was discarded. The ventricle was quickly
washed with normal saline, placed at −20 °C for 30 min,
cut into 5 equal portions, and then placed in 1 % triphe-
nyl tetrazolium chloride (TTC) solution in phosphate
buffer for 10 min. After TTC staining, the viable myo-
cardium was stained red and necrotic myocardium
remained pale. Ischemic zone and non-ischemic zone
were weighed. The weights of each ischemic area were
calculated using weight of the ischemic zone/total left
ventricular weight × 100 % as reported previously [29].
Statistical analysis
The data were expressed as mean ± S.D., a two-factor
repeated-measures analysis of variance (ANOVA) and
paired-test were performed using SPSS 16.0 statistical
software. The P-values <0.05 were considered to be sta-
tistically significant.
Results
Effect of SX on infarct size
To compare the visually observed effect of SX on anti-
ischemic, the infarct size of the ischemic hearts were
analysed. Figure 1 shows the percentage of infarct size of
hearts subjected to 180 min of ischemia. Post-ischemia
myocardium was associated with a 17.84 ± 2.83 % infarct
size which was consistently reduced by increasing con-
centrations of SX to 7.33 ± 4.39 % (P < 0.01, 6.40 mg/kg
SX), 6.03 ± 3.13 % (P <0.01, 12.80 mg/kg SX), and 5.55 ±
1.72 % (P <0.01, 25.60 mg/kg SX), in low, middle, and
high dose group respectively (Fig. 1). The same effect was
found in the ISD group which show no significant differ-
ence with SX (25.60 mg/kg) group. The lower panel in
Fig. 1b shown the infarcted (white) and viable (red) tissue,
and the infract areas treated with SX show unequivocal
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Fig. 1 Effects of SX on infarct size (upper panel, a) in dog hearts subjected to 180 min of ischemia. Each bar shows mean ± S.D. **P < 0.01 vs.
model group. Representative heart morphological photographs of infarct zone are shown on the lower panel (b). White areas indicate infarcted
tissues stained by TTC








30 60 90 120 180
Sham −35.47 ± 7.80 −31.40 ± 12.07 −28.14 ± 22.35 −34.21 ± 18.71 −31.54 ± 23.80 −32.10 ± 15.66 −25.93 ± 13.07
Model −18.85 ± 11.09 228.78 ± 122.39 209.86 ± 108.56 187.76 ± 74.35 182.10 ± 68.97 184.33 ± 71.08 189.54 ± 84.49
SX 25.60 −30.30 ± 36.01 239.47 ± 111.84 156.48 ± 127.59& 121.72 ± 93.09& 116.66 ± 76.64 94.62 ± 54.57*& 73.81 ± 69.97*&
SX 12.80 −39.02 ± 32.56 242.85 ± 70.06 155.22 ± 140.79& 144.12 ± 114.97& 147.20 ± 101.80& 135.71 ± 103.29& 98.11 ± 95.72*&&
SX 6.40 −43.29 ± 49.84 212.47 ± 72.40 127.46 ± 58.49& 130.03 ± 73.24& 146.50 ± 85.40& 132.43 ± 103.90& 140.03 ± 127.08&&
ISD 0.8 −20.17 ± 14.69 199.2 ± 92.22 122.5 ± 65.63 119.43 ± 64.96 107.89 ± 81.53 96.51 ± 85.91& 83.28 ± 79.61*&
All data were expressed as mean ± S.D. *P < 0.05, **P < 0.01 vs. model group; & P < 0.05, && P < 0.01 vs. Pre-Adm
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signs of improvement changed from whole white to red
alternating with white. There were significant differences
between the model group and SX groups.
Effect of SX on the degree and scope of myocardial
ischemia
Epicardial electrocardiogram was checked to compare the
degree and scope of myocardial ischemia during the experi-
ment. In the model group, the Σ-ST and N-ST were signifi-
cantly increased from −18.85 ± 11.09 mV to 228.78 ±
122.39 mV, and 0.33 ± 0.52 points to 24.67 ± 7.47 points re-
spectively (Tables 1 and 2). Following treatment with SX
and ISD, those indexes were significantly decreased at
180 min compared with the model group (P < 0.05). Add-
itionally the Σ-ST and N-ST of dogs treated with high dose
SX was significantly reduced by 69.18 % (from 239.47 ±
111.84 mV to 73.81 ± 69.97 mV, P < 0.05), and 26.75 %
(from 27.33 ± 2.25 points to 15.67 ± 6.56 points, P < 0.01),
respectively (Tables 1 and 2). After occlusion, epicardial
ECG changed dramatically and ST segment elevated signifi-
cantly (Fig. 2b). However, the higher dose (25.6 mg/kg) of
SX caused significant depression of ST segment on the epi-
cardial ECG (Fig. 2c).
Effect of SX on hemodynamic
Hemodynamic monitoring is one of the most important
methods to measure and interpret the performance of
the cardiovascular system. So the effects of SX on
hemodynamic were checked in the present study. And
the result shown no significant differences between all
the six groups at pre-occlusion (P > 0.05) (Table 3). More-
over no significant differences were observed after treat-
ment with regard to HR and ± dP/dt (P > 0.05). Compared
with model group, administration with SX high dose and
ISD caused a significant decrease in MAP (by 15.05 and
13.92 %, respectively), and in LVEDP (by 31.40 and
28.30 %) (P < 0.05). The LVSP was significantly decreased
in high, middle, low SX, and ISD group at 180 min post-
administration (P < 0.01). In the model group, CBF, MBF
decreased, and CVR were increased significantly (P < 0.05),
however, the trend were significantly reversed in the dogs
treated with SX and ISD showed in Table 3 (P < 0.05).
Effect of SX on the serum CK-MB, LDH, MDA and SOD
activity
The changes of the levels of serum cardiac enzymes
were confirmed during the acute myocardial ischemia.
In the present study, the effects of SX on CK-MB, LDH,
MDA, and SOD were checked (Fig. 3). Treatment with
all the three SX doses and ISD significantly reduced
serum CK-MB, LDH, MDA, and increased SOD levels in
90–180 min of post-occlusion compared with the model
group (P < 0.05, Fig. 3a, b, c, d). These results suggested
that SX could reduce lipid peroxidation and increase
superoxide dismutase resulting in the protection against
the myocardial ischemic damage.








30 60 90 120 180
Sham 0.83 ± 1.60 0.17 ± 0.41 0.17 ± 0.41 0.33 ± 0.52 0.17 ± 0.41 0.50 ± 1.22 0.00 ± 0.00
Model 0.33 ± 0.52 24.67 ± 7.47 25.83 ± 5.78 26.33 ± 5.24 26.67 ± 5.13 26.00 ± 5.51 26.67 ± 3.56
SX 25.60 1.33 ± 1.86 27.33 ± 2.25 21.33 ± 4.32& 17.33 ± 8.55& 17.33 ± 7.99*& 16.17 ± 7.47*&& 15.67 ± 6.56**&&
SX 12.80 0.86 ± 0.90 25.86 ± 3.08 16.57 ± 7.74&& 16.71 ± 6.99*&& 18.57 ± 4.96*& 18.71 ± 5.94*& 16.43 ± 6.68**&&
SX 6.40 1.83 ± 3.13 25.83 ± 2.32 19.67 ± 4.68& 19.17 ± 6.46& 19.83 ± 5.81& 18.83 ± 6.15& 18.67 ± 6.47*&
ISD 0.8 1.67 ± 1.97 25.33 ± 5.72 21.17 ± 6.82 21 ± 6.75 19 ± 9.19 15.83 ± 9.95& 16.33 ± 9.05*&
All data were expressed as mean ± S.D. *P < 0.05, **P < 0.01 vs. model group; & P < 0.05, && P < 0.01 vs. Pre-Adm
Fig. 2 Changes of epicardial ECG waveform after administration of SX in dogs. a, b and c represented epicardial ECG waterfall plot of sham,
model and SX high dose (25.6 mg/kg) group. Continuous epicardial ECG monitoring revealed that ST segment elevated after occlusion and
depressed after treatment SX
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Table 3 Hemodynamic parameters at pre-occlusion, pre-administration and post-administration (180 min)
Time Parameters
HR MAP LVSP LVEDP +dP/dtmax -dP/dtmix CBF MBF CVR
bpm mmHg mmHg mmHg mmHg/s mmHg/s ml/min ml/min.100 g mmHg.min/mL
Pre-Occ
Sham 175.35 ± 31.3 119.18 ± 14.43 147.27 ± 23.14 4.89 ± 3.36 3050.63 ± 542.34 −2610.66 ± 670.12 45.19 ± 2.41 161.31 ± 32.34 0.74 ± 0.09
Model 170.03 ± 35.3 123.88 ± 14.1 149.15 ± 13.74 3.45 ± 8.2 2850.71 ± 600.93 −2587.09 ± 477.81 47.86 ± 8.87 182.79 ± 60.94 0.79 ± 0.23
SX-H 167.88 ± 23.46 106.99 ± 21.01 135.26 ± 26.29 4.6 ± 4.2 2987.07 ± 825.57 −2329.83 ± 731.73 45.89 ± 7.32 163.02 ± 32.79 0.78 ± 0.21
SX-M 171.5 ± 25.06 106.92 ± 15.12 139.34 ± 7.64 3.68 ± 3.33 2764.46 ± 355 −2426.34 ± 459.77 44.05 ± 6.15 172.57 ± 43.87 0.76 ± 0.24
SX-L 167.4 ± 24.96 113.47 ± 16.49 136.85 ± 17.57 5.1 ± 2.21 2785.09 ± 635.7 −2533.04 ± 765.36 46.07 ± 13.52 145.87 ± 50.5 0.82 ± 0.25
ISD 171.16 ± 18.55 118.1 ± 20.7 146.88 ± 24.73 4.94 ± 1.9 2797.02 ± 481.73 −2328 ± 542.84 46.84 ± 2.81 185.2 ± 50.47 0.72 ± 0.18
Pre-Adm
Sham 175.97 ± 27.68 121.45 ± 16.64 149.37 ± 25.47 5.15 ± 0.53 3222.04 ± 595.88 −2720.74 ± 912.21 49.28 ± 7.95 171.94 ± 12.13 0.71 ± 0.09
Model 163.34 ± 33.96 104.26 ± 1.6 134.8 ± 10.66 7.69 ± 3.1 2445.67 ± 343.97 −2416.3 ± 310.43 44.64 ± 10.78 179.61 ± 55.94 0.74 ± 0.19
SX-H 160.02 ± 23.66 97.23 ± 18.85 131.07 ± 22.75 7.74 ± 3.25 2234.54 ± 642.44 −2110.49 ± 636.37 40.79 ± 8.1 149.81 ± 28.52 0.67 ± 0.19
SX-M 172.79 ± 26.4 102.51 ± 19.92 133.58 ± 9.97 6.81 ± 2.39 2549.35 ± 364.23 −2373.87 ± 334.64 44.68 ± 10.48 174.87 ± 58.35 0.65 ± 0.22
SX-L 165.27 ± 23.43 103.91 ± 15.53 125.56 ± 14.96 8.1 ± 3.1 2437.5 ± 482.9 −2308.27 ± 542.33 44.02 ± 12.37 137.31 ± 34.7 0.75 ± 0.18
ISD 165.43 ± 20.48 101.5 ± 23.81 112.53 ± 11.88 8.91 ± 1.35 2235.42 ± 509.53 −2037.27 ± 511.09 46.67 ± 10.35 175.73 ± 77.42 0.70 ± 0.16
Post-Adm
Sham 176.98 ± 33.58 111.3 ± 18.19 133.38 ± 18.78 4.7 ± 2.6 2830.94 ± 814 −2595.17 ± 718.67 50.37 ± 10.36 174.92 ± 18.42 0.68 ± 0.1
Model 168.9 ± 38.59 95.3 ± 12.26 132.34 ± 9.95 8.94 ± 1.87 1873.17 ± 532.67 −2120.28 ± 544.01 33.15 ± 9.75& 126.63 ± 27.83& 0.82 ± 0.19&
SX-H 184.27 ± 37.12 80.96 ± 5.29* 96.57 ± 12.05**&& 5.82 ± 2.65*& 1835.97 ± 141.59 −1862.88 ± 265.58 58.86 ± 13.3**& 219 ± 64.55*&& 0.36 ± 0.09**&&
SX-M 186.38 ± 36.32 90.9 ± 16.36 97.23 ± 22.2**&& 5.5 ± 3.05* 1946.72 ± 380.59 −1939.73 ± 720.86 49.66 ± 8.29* 205.25 ± 74.85*&& 0.48 ± 0.21*&
SX-L 174.25 ± 20.49 96.5 ± 17.19 109.33 ± 14.06** 6.09 ± 3.2* 2183.55 ± 423.96 −2081.71 ± 441.56 52.13 ± 13.41* 180.23 ± 53.75*& 0.55 ± 0.31&
ISD 167.28 ± 22.23 82.03 ± 2.51* 113.51 ± 6.79** 6.41 ± 3.19*& 2008.15 ± 175.04 −2024.36 ± 265.35 61 ± 13.55**& 222.55 ± 93.78*&& 0.4 ± 0.15**&&
All data were expressed as mean ± S.D. HR heart rate, MAP mean arterial pressure, LVSP left ventricular systolic pressure, LVEDP left ventricular end-diastolic pressure, +dP/dtmax maximal positive left ventricular dP/dt, -dP/dtmix


















Effect of SX on blood gas measurements
The blood gas analysis could reflect the oxygen metabol-
ism and oxygen consumption during acute myocardial
ischemia. Blood gas data of the six groups were shown
in Table 4. Compare with model group, a slight increase
in CaO2 was observed in groups treated with SX and
ISD, but it was not statistically significant (P > 0.05). Be-
sides, there were no differences in CvO2 in all groups.
After occlusion, the O2 extraction was increase gradually
in all group, the increase trend in SX (25.60 mg/kg)
and ISD group was significantly lower than model
group (P < 0.05), and the same trend were observed in
MVO2, but this change was not statistically significant
compared with model group.
Discussion
Previous clinical research indicates that, SX has been
shown to cause rapid remission of angina pectoris and
no serious side effects [30]. In our study, we demon-
strated that SX can reduce myocardium injuries after oc-
clusion of the LAD in anaesthetized dog. And the
present data demonstrate that: 1) SX can obviously re-
duce the levels of cardiac enzyme CK-MB, LDH and
MDA and increase the activity of SOD; 2) SX can mark-
edly reduce the myocardial infarct size, the degree
(∑-ST) and scope (N-ST) of myocardial ischemia; 3) SX
can reduce MBP, LVSP, CVR and increased CBF, MBF;
4) SX can significantly reduce myocardial oxygen extrac-
tion ratio. The research methods and implications of
these findings is discussed below.
In human disease, myocardial ischemia usually occurs
in different patterns, this various patterns of ischemic
myocardial necrosis occur for the most part against the
background of a coronary circulation widely compro-
mised by stenosing atherosclerosis [31, 32]. Conven-
tional myocardial ischemia model is induced by ligating
the left anterior descending artery. In fact this method
actually reflects myocardial infarction and it did not fully
represent disease characteristics of coronary heart dis-
ease, angina, and ultra-early clinical myocardial infarc-
tion. Because the early stage of these disease in clinical
state were incomplete occlusion whereas the model of
myocardial infarction was completely occulted. More-
over the drug hardly passes and plays its role in the
complete occlusion model. Therefore, this study at-
tempts to establish acute myocardial ischemia model by
incomplete ligating the left anterior descending artery to
reduce flow by 90 %, and evaluate the protective effect
of drugs on early myocardial ischemia. The animal spe-
cies of this research was dog because of that many
Fig. 3 Effects of SX on the serum CK-MB, LDH, MDA and SOD activity corresponding to (a, b, c and d). Serum enzyme indicators were detected
at −30 min (baseline), at 0 min (pre-administration), and at 30, 60, 90, 120, 180 min in post-administration. Adm Administration, Occ Occlusion.
Each bar shows mean ± S.D. *P < 0.05, **P < 0.01 vs. model group
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factors such as heart size, beating rate, and molecular
composition were more closer to human than with small
animals [33].
The technique of epicardial ECG was used in our
studies to delineate the area of ischemia. Epicardial ECG
ST-segment analysis in the characterization of myocardial
ischemia and infarction has received wide application [34].
This technique can accurately evaluate the extent and
magnitude of ischemic injury following coronary occlu-
sion and appears to be an indicator of myocardial ische-
mia [35, 36]. There is considerable evidence suggesting
that the epicardial S-T segment elevation directly reflects
myocardial cellular injury. Ross [37] reported that epicar-
dial ECG analysis was useful for detecting acute changes
in the severity of ischemic injury, and correlated with
biochemical changes, regional myocardial blood flow,
histologic changes, and creating phosphokinase (CPK),
myocardial electrolyte alterations. Our data indicated that
SX could markedly lower the degree of myocardial ische-
mia (Σ-ST) and reduce the scope of ischemia (N-ST) in
dogs, which was in accordance with the result of reducing
infarction and other specific parameters of ischemic
damage.
Previous studies showed that acute myocardial ische-
mia can create numerous free radicals that cause damage
to the cellular membranes as a result of producing lipid
peroxidation [38]. When cell membrane becomes per-
meable or rupture, LDH, and CK spread out from the
damaged tissues to the blood stream and served the
diagnostic markers of myocardial tissue injury [39].
MDA was diagnostic indices of lipid peroxidation and
peroxidative tissue injury [40, 41]. However, SOD en-
zyme can protect the cell from superoxide toxicity
through catalyzing the conversion of superoxide free
radicals to oxygen and hydrogen peroxide in all cells
[42]. Our data showed that the levels of MDA, LDH,
and CK-MB were decreased and SOD was increased sig-
nificantly in SX administered group, suggesting that SX
may reduce lipid peroxidation resulting in the protection
against the myocardial ischemic damage.
Table 4 Blood gas analysis parameters at pre-occlusion, pre-administration and post-administration (180 min)
Group Pre-Occ Pre-Adm Post-Adm (min)
30 60 90 120 180
CvO2 (vol %) Sham 11.01 ± 4.84 11.3 ± 4.26 10.93 ± 4.44 8.73 ± 4.41 8.67 ± 3.81 8.05 ± 3.53 7.88 ± 3.27
Model 11.38 ± 2.8 10.36 ± 4.1 9.24 ± 4.19 7.99 ± 3.64 6.57 ± 3.3 6.57 ± 3.35 5.43 ± 3.01
SX-H 12.06 ± 3.2 11.32 ± 4.36 10.47 ± 2.44 9.64 ± 1.95 8.38 ± 1.68 8.12 ± 2.29 7.38 ± 2.55
SX-M 12.67 ± 3.63 12.01 ± 3.8 10.76 ± 4.14 9.99 ± 4.27 8.94 ± 4.19 8.94 ± 4.66 8.35 ± 5.17
SX-L 12.01 ± 2.82 9.53 ± 3.37 8.5 ± 3 8.81 ± 4.2 8.64 ± 3.31 7.47 ± 2.27 5.96 ± 2.73
ISD 11.94 ± 1.21 11.44 ± 1.34 11.51 ± 2.16 10.31 ± 1.77 9.95 ± 2.65 9.78 ± 3.03 8.52 ± 3.42
CaO2 (vol %) Sham 19 ± 0.68 19.21 ± 0.41 18.99 ± 0.45 18.81 ± 0.47 18.82 ± 0.41 18.68 ± 0.64 18.74 ± 0.73
Model 18.78 ± 1.2 18.32 ± 2.32 17.83 ± 1.02 17.4 ± 1.8 17.34 ± 2.04 17.14 ± 2.19 16.86 ± 2.07
SX-H 19 ± 0.38 18.64 ± 0.53 18.46 ± 0.69 18.31 ± 0.78 18.2 ± 0.85 18.2 ± 0.58 17.81 ± 1.17
SX-M 18.82 ± 0.43 18.54 ± 0.78 18.42 ± 0.88 18.22 ± 1.22 18.22 ± 1 18.09 ± 0.94 17.6 ± 1.18
SX-L 18.77 ± 0.42 18.44 ± 0.76 18.03 ± 0.97 17.79 ± 0.84 17.53 ± 0.9 17.22 ± 1.03 16.53 ± 1.24
ISD 18.45 ± 0.91 18.22 ± 0.71 18.04 ± 0.56 18.17 ± 0.96 17.77 ± 0.95 17.74 ± 0.77 17.61 ± 1.41
O2 Extr (%) Sham 0.36 ± 0.22 0.37 ± 0.21 0.37 ± 0.21 0.5 ± 0.25 0.5 ± 0.2 0.58 ± 0.21 0.58 ± 0.21
Model 0.42 ± 0.14 0.47 ± 0.19 0.53 ± 0.21 0.59 ± 0.17 0.67 ± 0.13 0.66 ± 0.16 0.71 ± 0.15
SX-H 0.36 ± 0.17 0.39 ± 0.24 0.43 ± 0.13 0.47 ± 0.12 0.54 ± 0.09* 0.55 ± 0.13* 0.59 ± 0.11*
SX-M 0.33 ± 0.2 0.35 ± 0.22 0.42 ± 0.23 0.46 ± 0.23 0.51 ± 0.23 0.51 ± 0.25 0.53 ± 0.28
SX-L 0.36 ± 0.16 0.48 ± 0.19 0.53 ± 0.16 0.51 ± 0.22 0.51 ± 0.16 0.57 ± 0.11 0.64 ± 0.15
ISD 0.35 ± 0.07 0.37 ± 0.09 0.36 ± 0.13 0.43 ± 0.1 0.44 ± 0.14* 0.45 ± 0.17* 0.51 ± 0.2*
MVO2 (ml/min · 100 g) Sham 9.72 ± 5.64 10.15 ± 4.05 9.95 ± 4.4 13.95 ± 7.14 15.5 ± 8.73 17.94 ± 9.83 18.52 ± 7.22
Model 10.79 ± 5.28 15.53 ± 10.01 16.58 ± 8.45 19.24 ± 7.82 20.64 ± 7.62 23.54 ± 8.18 26.36 ± 6.74
SX-H 9.92 ± 4.5 11.05 ± 7.99 10.81 ± 2.06 13.36 ± 3.85 15.75 ± 5.73 16.16 ± 7.54 19.8 ± 5.45
SX-M 7.79 ± 2.51 9.13 ± 4.83 9.36 ± 2.39 9.93 ± 3.8 13.05 ± 7.04 16.47 ± 10.73 18.03 ± 8.71
SX-L 8.75 ± 5.14 11.31 ± 3.73 12.44 ± 2.06 13.67 ± 5.81 14.82 ± 4.77 15.62 ± 3.61 17.05 ± 4.04
ISD 11.7 ± 1.36 13.59 ± 4.41 11.18 ± 3.09 14.51 ± 2.54 14.31 ± 3.46 16.22 ± 5.67 21.92 ± 12.7
All data were expressed as mean ± S.D. CvO2 oxygen content of venous, CaO2 oxygen content of arterial, O2 Extr oxygen extraction ratio, MVO2 myocardial oxygen
consumption. *P < 0.05 vs. model group
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In this study, SX increased coronary blood flow sub-
stantially and decreased arterial pressure slightly as cor-
onary vascular resistance was reduced. Since heart rate
and myocardial contractility (dP/dtmax) was held con-
stant, the increase in coronary blood flow was due to an
augmentation in stroke volume and expansion of the
coronary arteries. After myocardial, cardiac preload, and
afterload gradually increased eventually leading to more
debilitating heart function [43, 44]. LVEDP and CVR were
used as indicators of cardiac preload and afterload [45].
The decrease in preload (LVEDP, by −31.4 %) and after-
load (CVR, by −56.1 %) of SX high dose group suggested
the beneficial effect of SX in reducing cardiac load.
Other previous researches suggested that, a rapid in-
crease of myocardial oxygen demand occurred in ische-
mia, and influence myocardial oxygen demand may
aggravate or alleviate symptoms of myocardial ischemia
[46]. The balance between oxygen supply and demand is
of paramount importance for the heart since it deter-
mines where oxygen need exceeds oxygen supply [47].
Clinical observations suggested that the associated re-
duction of myocardial oxygen needs is often associated
with relief of angina in patients with angina treatment of
the hypermetabolic state [46]. Reducing myocardial oxy-
gen consumption produced potent anti-ischemic effects
[48]. In the current study, a significant decreasing of
myocardial oxygen extraction was found in groups
treated with SX, and the same trend was observed in
myocardial oxygen consumption.
Conclusions
The present research suggests that SX exert notable anti-
anginal ischaemia effect, and indicates SX as an effective
traditional Chinese medicine for the treatment of ischemic
heart disease. The mechanism of actions related to SX can
improve hemodynamics, expand coronary artery, and re-
duce myocardial workload and oxygen demand.
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